SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-040960
Filing Date
2023-08-10
Accepted
2023-08-10 07:30:56
Documents
78
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q verv-20230630.htm   iXBRL 10-Q 3224701
2 EX-10.1 verv-ex10_1.htm EX-10.1 1161442
3 EX-10.2 verv-ex10_2.htm EX-10.2 311755
4 EX-31.1 verv-ex31_1.htm EX-31.1 21038
5 EX-31.2 verv-ex31_2.htm EX-31.2 21043
6 EX-32.1 verv-ex32_1.htm EX-32.1 11951
7 EX-32.2 verv-ex32_2.htm EX-32.2 11917
  Complete submission text file 0000950170-23-040960.txt   11506601

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT verv-20230630_lab.xml EX-101.LAB 451875
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT verv-20230630_def.xml EX-101.DEF 197231
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT verv-20230630_pre.xml EX-101.PRE 334371
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT verv-20230630.xsd EX-101.SCH 58816
12 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT verv-20230630_cal.xml EX-101.CAL 41147
72 EXTRACTED XBRL INSTANCE DOCUMENT verv-20230630_htm.xml XML 1741514
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40489 | Film No.: 231157186
SIC: 2834 Pharmaceutical Preparations